Article

A2B adenosine receptor dampens hypoxia-induced vascular leak

Departments of Anesthesiology and Intensive Care , Tübingen University Hospital, Tübingen, Germany.
Blood (Impact Factor: 9.78). 03/2008; 111(4):2024-35. DOI: 10.1182/blood-2007-10-117044
Source: PubMed

ABSTRACT Extracellular adenosine has been implicated in adaptation to hypoxia and previous studies demonstrated a central role in vascular responses. Here, we examined the contribution of individual adenosine receptors (ARs: A1AR/A2AAR/A2BAR/A3AR) to vascular leak induced by hypoxia. Initial profiling studies revealed that siRNA-mediated repression of the A2BAR selectively increased endothelial leak in response to hypoxia in vitro. In parallel, vascular permeability was significantly increased in vascular organs of A2BAR(-/-)-mice subjected to ambient hypoxia (8% oxygen, 4 hours; eg, lung: 2.1 +/- 0.12-fold increase). By contrast, hypoxia-induced vascular leak was not accentuated in A1AR(-/-)-, A2AAR(-/-)-, or A3AR(-/-)-deficient mice, suggesting a degree of specificity for the A2BAR. Further studies in wild type mice revealed that the selective A2BAR antagonist PSB1115 resulted in profound increases in hypoxia-associated vascular leakage while A2BAR agonist (BAY60-6583 [2-[6-amino-3,5-dicyano-4-[4-(cyclopropylmethoxy)-. phenyl]pyridin-2-ylsulfanyl]acetamide]) treatment was associated with almost complete reversal of hypoxia-induced vascular leakage (eg, lung: 2.0 +/- 0.21-fold reduction). Studies in bone marrow chimeric A2BAR mice suggested a predominant role of vascular A2BARs in this response, while hypoxia-associated increases in tissue neutrophils were, at least in part, mediated by A2BAR expressing hematopoietic cells. Taken together, these studies provide pharmacologic and genetic evidence for vascular A2BAR signaling as central control point of hypoxia-associated vascular leak.

Full-text

Available from: Linda F Thompson, Aug 04, 2014
0 Followers
 · 
139 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Sleep is an integral and constitutive part of life, invariably observed in animals with even a simple nervous system. Importantly, sleep is an active and highly regulated state. Sleep propensity or sleep need and its best established biological marker, electroencephalographic (EEG) slow-wave (or delta) activity, is tightly associated to prior wakefulness and sleep and is homeostatically regulated. Sleep need may be considered an essential aspect of life, just like feeding, drinking, and procreation. Sleep, therefore, likely developed in a primordial state of evolution and should either aid or, at least, not interfere with other essential biological aspects of life such as metabolisms and reproduction. Consistent with this view, brain circuitries regulating sleep need, metabolism, and reward appear to involve the basal ganglia and are tightly linked. They may sense changes in the organism’s major cellular energy store, adenosine-tri-phosphate (ATP), and its derivative adenosine, and act in concert with other important neuromodulatory systems including dopamine, glutamate, and hypocretin.
    01/2015; 1(1):1-11. DOI:10.1007/s40675-014-0007-3
  • Source
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Adenosine is a neuromodulator mostly acting through A1 (inhibitory) and A2A (excitatory) receptors in the brain. A2B receptors (A2 B R) are Gs/q -protein-coupled receptors with low expression in the brain. As A2 B R function is largely unknown, we have now explored their role in the mouse hippocampus. We performed electrophysiological extracellular recordings in mouse hippocampal slices, and immunological analysis of nerve terminals and glutamate release in hippocampal slices and synaptosomes. Additionally, A2 B R-knockout (A2 B R-KO) and C57/BL6 mice were submitted to a behavioural test battery (open field, elevated plus-maze, Y-maze). The A2 B R agonist BAY60-6583 (300 nm) decreased the paired-pulse stimulation ratio, an effect prevented by the A2 B R antagonist MRS 1754 (200 nM) and abrogated in A2 B R-KO mice. Accordingly, A2 B R immunoreactivity was present in 73 ± 5% of glutamatergic nerve terminals, i.e. those immunopositive for vesicular glutamate transporters. Furthermore, BAY 60-6583 attenuated the A1 R control of synaptic transmission, both the A1 R inhibition caused by 2-chloroadenosine (0.1-1 μm) and the disinhibition caused by the A1 R antagonist DPCPX (100 nm), both effects prevented by MRS 1754 and abrogated in A2 B R-KO mice. BAY 60-6583 decreased glutamate release in slices and also attenuated the A1 R inhibition (CPA 100 nm). A2 B R-KO mice displayed a modified exploratory behaviour with an increased time in the central areas of the open field, elevated plus-maze and the Y-maze and no alteration of locomotion, anxiety or working memory. We conclude that A2 B R are present in hippocampal glutamatergic terminals where they counteract the predominant A1 R-mediated inhibition of synaptic transmission, impacting on exploratory behaviour. © 2015 Federation of European Neuroscience Societies and John Wiley & Sons Ltd.
    European Journal of Neuroscience 02/2015; 41(7). DOI:10.1111/ejn.12851 · 3.67 Impact Factor